دورة المؤشرنت للتحليل الفني
50 دينار كويتي
Dvax ...........وهدوء ماقبل العاصفه
- بادئ الموضوع stockolic
- تاريخ البدء
girgish1
عضو نشط
http://biz.yahoo.com/bw/090804/20090804006237.html?.v=1
http://biz.yahoo.com/bw/090804/20090804006254.html?.v=1
ليس ما توقعناه ولكن خيرة إن شاء الله
http://biz.yahoo.com/bw/090804/20090804006254.html?.v=1
ليس ما توقعناه ولكن خيرة إن شاء الله
وليد العربي
عضو نشط
- التسجيل
- 22 فبراير 2005
- المشاركات
- 340
أخي الحبيب قرقش ممكن لو تكرمت ترجمة مختصرة للخبر
girgish1
عضو نشط
تامر أمر
والسيئ في الخبر انه ستكون هناك فترة ليست قصيرة قبل إنتهاء التجارب على الاشخاص المريضين وفترة اخرى قبل الموافقة او الرفض. يعني السالفة مطولة. والامل الوحيد حتى يرتفع السعر الى ما فوق 4 دولار هو إستحواذ شركة كبيرة لديفاكس اي شركتنا.
والله اعلى وأعلم
الشركة تتفق مع إدارة الغذاء والدواء الامريكية على آلية مواصلة التجريب للمرحلة الثالثة لعقار التحصين ضد مرض الالتهاب الفيروسي الوبائي للاشخاص المصابين بامراض اخرى كالايدز وامراض التنفس واعتبار التجربة للمرحلة الثالثة للإشخاص الاصحاء ناجحة. أما الخير الثاني فهو نتائج الشركة المالية.
والسيئ في الخبر انه ستكون هناك فترة ليست قصيرة قبل إنتهاء التجارب على الاشخاص المريضين وفترة اخرى قبل الموافقة او الرفض. يعني السالفة مطولة. والامل الوحيد حتى يرتفع السعر الى ما فوق 4 دولار هو إستحواذ شركة كبيرة لديفاكس اي شركتنا.
والله اعلى وأعلم
q8sniper
عضو نشط
- التسجيل
- 28 يونيو 2005
- المشاركات
- 139
http://biz.yahoo.com/e/090805/dvax8-k.html
Form 8-K for DYNAVAX TECHNOLOGIES CORP
--------------------------------------------------------------------------------
5-Aug-2009
Results of Operations and Financial Condition, Other Events, Financial
Item 2.02. Results of Operations and Financial Condition
On August 4, 2009, Dynavax Technologies Corporation ("Dynavax"), issued a press release announcing its financial results for second quarter ended June 30, 2009. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 8.01. Other Events
On August 4, 2009, Dynavax issued a press release titled "Dynavax Announces Path for HEPLISAV(TM)Hepatitis B Vaccine Development." A copy of the press release is attached as Exhibit 99.2 to this current report and is incorporated herein by reference
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated August 4, 2009 titled "Dynavax Announces Second Quarter 2009 Financial Results."
99.2 Press Release, dated August 4, 2009 titled "Dynavax Announces Path for HEPLISAV(TM) Hepatitis B Vaccine Development."
Form 8-K for DYNAVAX TECHNOLOGIES CORP
--------------------------------------------------------------------------------
5-Aug-2009
Results of Operations and Financial Condition, Other Events, Financial
Item 2.02. Results of Operations and Financial Condition
On August 4, 2009, Dynavax Technologies Corporation ("Dynavax"), issued a press release announcing its financial results for second quarter ended June 30, 2009. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 8.01. Other Events
On August 4, 2009, Dynavax issued a press release titled "Dynavax Announces Path for HEPLISAV(TM)Hepatitis B Vaccine Development." A copy of the press release is attached as Exhibit 99.2 to this current report and is incorporated herein by reference
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated August 4, 2009 titled "Dynavax Announces Second Quarter 2009 Financial Results."
99.2 Press Release, dated August 4, 2009 titled "Dynavax Announces Path for HEPLISAV(TM) Hepatitis B Vaccine Development."
وليد العربي
عضو نشط
- التسجيل
- 22 فبراير 2005
- المشاركات
- 340
بيض الله وجهك أخوي قرقش وجاك الله خيرا السؤال هنا هل هناك محاولات حقيقية أو مفاوضات سابقة للاستحواذ على ديفاكس
q8sniper
عضو نشط
- التسجيل
- 28 يونيو 2005
- المشاركات
- 139
q8sniper
عضو نشط
- التسجيل
- 28 يونيو 2005
- المشاركات
- 139
BERKELEY, Calif., Aug 12, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (DVAX, Trade ) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAV(TM) Phase 3 investigational adult hepatitis B vaccine in Europe.
In a Scientific Advice letter, EMEA expressed a general agreement with Dynavax's proposed plan to develop HEPLISAV for adult populations that are less responsive to current licensed hepatitis B vaccines, including adults over 40 years of age, individuals with chronic kidney disease, and other groups. In addition, EMEA suggested that Dynavax consider the development of HEPLISAV for adults under 40 years of age who need rapid protection, a group that includes emergency personnel, healthcare workers and international travelers.
"As we advance our development plans for HEPLISAV, EMEA's scientific advice supports expansion of our targeted population in Europe to include subjects who need rapid protection against hepatitis B infection," commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. "A vaccine that demonstrates potential to provide faster and better protection than current vaccines could transform vaccination regimens and outcomes, particularly for individuals with increased risk of infection."
About HEPLISAV
HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. Over 2,500 individuals have been vaccinated with HEPLISAV to date.
Dynavax has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
About Hepatitis B Vaccines
Hepatitis B is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. There is no cure for hepatitis B and disease prevention through effective vaccination is critical to reducing the spread of the disease. The total worldwide market for adult hepatitis B vaccines is estimated at over $500 million annually.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com .
Forward Looking Statements
This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties, including statements related to the nature of communications with EMEA regarding HEPLISAV, submissions of documents, and potential clinical trials, and whether those submissions and trials may be acceptable to the EMEA. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether and when the FDA will remove the clinical hold on HEPLISAV, whether HEPLISAV can be further developed, financed or commercialized, or even if further development is permitted, that successful clinical development and regulatory approval can occur in a timely manner or without significant additional studies or difficulties or delays in development, the Company's ability to obtain additional financing to support its operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
SOURCE: Dynavax Technologies Corporation
Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
afigueroa@dynavax.com
In a Scientific Advice letter, EMEA expressed a general agreement with Dynavax's proposed plan to develop HEPLISAV for adult populations that are less responsive to current licensed hepatitis B vaccines, including adults over 40 years of age, individuals with chronic kidney disease, and other groups. In addition, EMEA suggested that Dynavax consider the development of HEPLISAV for adults under 40 years of age who need rapid protection, a group that includes emergency personnel, healthcare workers and international travelers.
"As we advance our development plans for HEPLISAV, EMEA's scientific advice supports expansion of our targeted population in Europe to include subjects who need rapid protection against hepatitis B infection," commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. "A vaccine that demonstrates potential to provide faster and better protection than current vaccines could transform vaccination regimens and outcomes, particularly for individuals with increased risk of infection."
About HEPLISAV
HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. Over 2,500 individuals have been vaccinated with HEPLISAV to date.
Dynavax has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
About Hepatitis B Vaccines
Hepatitis B is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. There is no cure for hepatitis B and disease prevention through effective vaccination is critical to reducing the spread of the disease. The total worldwide market for adult hepatitis B vaccines is estimated at over $500 million annually.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com .
Forward Looking Statements
This press release contains "forward-looking statements," that are subject to a number of risks and uncertainties, including statements related to the nature of communications with EMEA regarding HEPLISAV, submissions of documents, and potential clinical trials, and whether those submissions and trials may be acceptable to the EMEA. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether and when the FDA will remove the clinical hold on HEPLISAV, whether HEPLISAV can be further developed, financed or commercialized, or even if further development is permitted, that successful clinical development and regulatory approval can occur in a timely manner or without significant additional studies or difficulties or delays in development, the Company's ability to obtain additional financing to support its operations, possible claims against the Company based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
SOURCE: Dynavax Technologies Corporation
Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
afigueroa@dynavax.com
دورة المؤشرنت للتحليل الفني
50 دينار كويتي